UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038927
Receipt number R000044325
Scientific Title Association between Corticotropin-Releasing Hormone peptide expression and cancer progrssion as well as emotion in pancreatic cancer
Date of disclosure of the study information 2019/12/25
Last modified on 2019/12/19 11:32:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association between Corticotropin-Releasing Hormone peptide expression and cancer progrssion as well as emotion in pancreatic cancer

Acronym

Association between CRH peptide expression and cancer progrssion as well as emotion in pancreatic cancer

Scientific Title

Association between Corticotropin-Releasing Hormone peptide expression and cancer progrssion as well as emotion in pancreatic cancer

Scientific Title:Acronym

Association between CRH peptide expression and cancer progrssion as well as emotion in pancreatic cancer

Region

Japan


Condition

Condition

pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Association between CRH peptide expression and cancer progrssion as well as emotion in pancreatic cancer

Basic objectives2

Others

Basic objectives -Others

QOL, Depression

Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Association between CRH expression in tumor tissues and recurrence

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Possibly resectable of Pancreatic cancer
2. ECOG PS of 0 or 1
3. tolerable function of bone marrow, liver and kidney..
4. Possible oral intake.
5. written informed consent
6. over 20 years old

Key exclusion criteria

1. Pulmonary fibrosis or interstitial pneumonitis
2. Patients expectd R2 resection
3. Patients with synclonous double cancer
4. Active infection
5. HBs Ag positive
6. Patients requiring the administration of flucytosine, phenytoin or warfarin potassium
7. Patients who are pregnant or possibly pregnant.
8.The patient judged to be unsuitable by attending doctor

Target sample size

140


Research contact person

Name of lead principal investigator

1st name Michiaki
Middle name
Last name Unno

Organization

Tohoku University Graduate School of Medicine

Division name

Department of Surgery

Zip code

980-8575

Address

2-1 seiryo-machi, Aoba-ku, Sendai, Japan

TEL

022-717-7201

Email

m_unno@surg.med.tohoku.ac.jp


Public contact

Name of contact person

1st name Naoko
Middle name SATO
Last name Sato

Organization

Tohoku University Graduate School of Medicine

Division name

Behavioral Medicine

Zip code

980-8575

Address

2-1 seiryo-machi, Aoba-ku, Sendai, Japan

TEL

022-717-8160

Homepage URL


Email

naoko-s@med.tohoku.ac.jp


Sponsor or person

Institute

Tohoku University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

JSPS KAKENHI Grant

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tohoku University Graduate School of Medicine

Address

2-1, seiryo-machi

Tel

022-717-8007

Email

med-kenkyo@grp.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 05 Month 14 Day

Date of IRB

2019 Year 05 Month 30 Day

Anticipated trial start date

2019 Year 12 Month 01 Day

Last follow-up date

2024 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

QOL


Management information

Registered date

2019 Year 12 Month 19 Day

Last modified on

2019 Year 12 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044325


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name